Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2016

01-04-2016 | Review

Inhibitor of growth-4 is a potential target for cancer therapy

Authors: Shuping Yuan, Jianhua Jin, Juanjuan Shi, Yongzhong Hou

Published in: Tumor Biology | Issue 4/2016

Login to get access

Abstract

The inhibitor of growth-4 (ING-4) belongs to the inhibitor of growth (ING) family that is a type II tumor suppressor gene including five members (ING1-5). As a tumor suppressor, ING4 inhibits tumor growth, invasion, and metastasis by multiple signaling pathways. In addition to that, ING4 can facilitate cancer cell sensitivity to chemotherapy and radiotherapy. Although ING4 loss is observed for many types of cancers, increasing evidences show that ING4 can be used for gene therapy. In this review, the recent progress of ING4 regulating tumorigenesis is discussed.
Literature
1.
Feng X, Hara Y, Riabowol K. Different HATS of the ING1 gene family. Trends Cell Biol. 2002;12:532–8.CrossRefPubMed
2.
He GH, Helbing CC, Wagner MJ, Sensen CW, Riabowol K. Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol. 2005;22:104–16.CrossRefPubMed
3.
Russell M, Berardi P, Gong W, Riabowol K. Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis. Exp Cell Res. 2006;312:951–61.CrossRefPubMed
4.
Hu RM, Han ZG, Song HD, Peng YD, Huang QH, Ren SX, et al. Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A. 2000;97:9543–8.CrossRefPubMedPubMedCentral
5.
Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E, et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature. 2004;428:328–32.CrossRefPubMed
6.
Gunduz M, Ouchida M, Fukushima K, Ito S, Jitsumori Y, Nakashima T, et al. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene. 2002;21:4462–70.CrossRefPubMed
7.
Unoki M, Shen JC, Zheng ZM, Harris CC. Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J Biol Chem. 2006;281:34677–86.CrossRefPubMed
8.
Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, et al. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 2003;63:2373–8.PubMed
9.
Doyon Y, Cayrou C, Ullah M, Landry AJ, Cote V, Selleck W, et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell. 2006;21:51–64.CrossRefPubMed
10.
Kim S, Chin K, Gray JW, Bishop JM. A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci U S A. 2004;101:16251–6.CrossRefPubMedPubMedCentral
11.
Moreno A, Soleto I, Garcia-Sanz P, Moreno-Bueno G, Palmero I. ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth. Oncogene. 2014;33:1945–53.CrossRefPubMed
12.
Mathema VB, Koh YS. Inhibitor of growth-4 mediates chromatin modification and has a suppressive effect on tumorigenesis and innate immunity. Tumour Biol. 2012;33:1–7.CrossRefPubMed
13.
Sun J, Shen Q, Lu H, Jiang Z, Xu W, Feng L, et al. Oncogenic Ras suppresses ING4-TDG-Fas axis to promote apoptosis resistance. Oncotarget. 2015;6:41997–2007.PubMedPubMedCentral
14.
Yan R, He L, Li Z, Han X, Liang J, Si W, et al. SCF(JFK) is a bona fide E3 ligase for ING4 and a potent promoter of the angiogenesis and metastasis of breast cancer. Genes Dev. 2015;29:672–85.CrossRefPubMedPubMedCentral
15.
Yao H, Wang K, Wang Y, Wang S, Li J, Lou J, et al. Enhanced blood–brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system. Biomaterials. 2015;37:345–52.CrossRefPubMed
16.
Xu M, Xie Y, Sheng W, Miao J, Yang J. Adenovirus-mediated ING4 gene transfer in osteosarcoma suppresses tumor growth via induction of apoptosis and inhibition of tumor angiogenesis. Technol Cancer Res Treat. 2015;14:369–78.CrossRefPubMed
17.
Zhao Y, Li Z, Sheng W, Miao J, Yang J. Radiosensitivity by ING4-IL-24 bicistronic adenovirus-mediated gene cotransfer on human breast cancer cells. Cancer Gene Ther. 2013;20:38–45.CrossRefPubMed
18.
Gunduz M, Nagatsuka H, Demircan K, Gunduz E, Cengiz B, Ouchida M, et al. Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene. 2005;356:109–17.CrossRefPubMed
19.
Mao ZL, He SB, Sheng WH, Dong XQ, Yang JC. Adenovirus-mediated ING4 expression reduces multidrug resistance of human gastric carcinoma cells in vitro and in vivo. Oncol Rep. 2013;30:2187–94.PubMed
20.
Ling C, Xie Y, Zhao D, Zhu Y, Xiang J, Yang J. Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy. Cancer Gene Ther. 2012;19:697–706.CrossRefPubMed
21.
Li J, Li G. Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1. Cancer Res. 2010;70:10445–53.CrossRefPubMed
22.
Xu Y, Jin J, Zhang W, Zhang Z, Gao J, Liu Q, et al. EGFR/MDM2 signaling promotes NFkappaB activation via PPARgamma degradation. Carcinogenesis. 2015.
23.
Gao J, Liu Q, Xu Y, Gong X, Zhang R, Zhou C, et al. PPARalpha induces cell apoptosis by destructing Bcl2. Oncotarget. 2015.
24.
Hou Y, Gao J, Xu H, Xu Y, Zhang Z, Xu Q, et al. PPARgamma E3 ubiquitin ligase regulates MUC1-C oncoprotein stability. Oncogene. 2013.
25.
Yan A, Yang C, Chen Z, Li C, Cai L. MiR-761 promotes progression and metastasis of non-small cell lung cancer by targeting ING4 and TIMP2. Cell Physiol Biochem. 2015;37:55–66.CrossRefPubMed
26.
Cao L, Chen S, Zhang C, Chen C, Lu N, Jiang Y, et al. ING4 enhances paclitaxel’s effect on colorectal cancer growth in vitro and in vivo. Int J Clin Exp Pathol. 2015;8:2919–27.PubMedPubMedCentral
27.
Kim S, Welm AL, Bishop JM. A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer Res. 2010;70:5155–62.CrossRefPubMedPubMedCentral
28.
Byron SA, Min E, Thal TS, Hostetter G, Watanabe AT, Azorsa DO, et al. Negative regulation of NF-kappaB by the ING4 tumor suppressor in breast cancer. PLoS One. 2012;7, e46823.CrossRefPubMedPubMedCentral
29.
Berger PL, Frank SB, Schulz VV, Nollet EA, Edick MJ, Holly B, et al. Transient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis. Cancer Res. 2014;74:3357–68.CrossRefPubMedPubMedCentral
30.
Nanding A, Tang L, Cai L, Chen H, Geng J, Liu X, et al. Low ING4 protein expression detected by paraffin-section immunohistochemistry is associated with poor prognosis in untreated patients with gastrointestinal stromal tumors. Gastric Cancer. 2014;17:87–96.CrossRefPubMed
31.
Zhang H, Zhou X, Xu C, Yang J, Xiang J, Tao M, et al. Synergistic tumor suppression by adenovirus-mediated ING4/PTEN double gene therapy for gastric cancer. Cancer Gene Ther. 2015.
32.
Lou C, Jiang S, Guo X, Dong XS. ING4 is negatively correlated with microvessel density in colon cancer. Tumour Biol. 2012;33:2357–64.CrossRefPubMed
33.
Liu Y, Yu L, Wang Y, Zhang Y, Wang Y, Zhang G. Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density. J Cancer Res Clin Oncol. 2012;138:647–55.CrossRefPubMed
34.
Wang QS, Li M, Zhang LY, Jin Y, Tong DD, Yu Y, et al. Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology. 2010;57:271–81.CrossRefPubMed
35.
Klironomos G, Bravou V, Papachristou DJ, Gatzounis G, Varakis J, Parassi E, et al. Loss of inhibitor of growth (ING-4) is implicated in the pathogenesis and progression of human astrocytomas. Brain Pathol. 2010;20:490–7.CrossRefPubMed
36.
Fang F, Luo LB, Tao YM, Wu F, Yang LY. Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomark Prev. 2009;18:409–16.CrossRef
37.
Xie Y, Zhang H, Sheng W, Xiang J, Ye Z, Yang J. Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis. Cancer Lett. 2008;271:105–16.CrossRefPubMed
38.
Xie YF, Sheng W, Xiang J, Zhang H, Ye Z, Yang J. Adenovirus-mediated ING4 expression suppresses pancreatic carcinoma cell growth via induction of cell-cycle alteration, apoptosis, and inhibition of tumor angiogenesis. Cancer Biother Radiopharm. 2009;24:261–9.CrossRefPubMed
39.
Wang Y, Yang J, Sheng W, Xie Y, Liu J. Adenovirus-mediated ING4/PTEN double tumor suppressor gene co-transfer modified by RGD enhances antitumor activity in human nasopharyngeal carcinoma cells. Int J Oncol. 2015;46:1295–303.PubMed
40.
Wu J, Zhu Y, Xu C, Xu H, Zhou X, Yang J, et al. Adenovirus-mediated p53 and ING4 gene cotransfer elicits synergistic antitumor effects through enhancement of p53 acetylation in breast cancer. Oncol Rep. 2016;35:243–52.PubMed
41.
Han Z, Zhou C, Sun B, Yan Q, Zhang J. Experimental studies on the inhibition of adenovirus-ING4-OSM therapy on nasopharyngeal carcinoma proliferation in vitro and in vivo. Cell Biochem Biophys. 2014;70:1573–8.CrossRefPubMed
42.
Conner J, Braidwood L. Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy. Cancer Gene Ther. 2012;19:499–507.CrossRefPubMed
43.
44.
45.
Stancovski I, Baltimore D. NF-kappaB activation: the I kappaB kinase revealed? Cell. 1997;91:299–302.CrossRefPubMed
46.
Ghosh S, Baltimore D. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature. 1990;344:678–82.CrossRefPubMed
47.
Hou Y, Mortimer L, Chadee K. Entamoeba histolytica cysteine proteinase 5 binds integrin on colonic cells and stimulates NFkappaB-mediated pro-inflammatory responses. J Biol Chem. 2010;285:35497–504.CrossRefPubMedPubMedCentral
48.
Xu H, You M, Shi H, Hou Y. Ubiquitin-mediated NFkappaB degradation pathway. Cell Mol Immunol. 2014.
49.
Hou Y, Moreau F, Chadee K. PPARgamma is an E3 ligase that induces the degradation of NFkappaB/p65. Nat Commun. 2012;3:1300.CrossRefPubMed
50.
Hou Y, Zhang Z, Xu Q, Wang H, Xu Y, Chen K. Inhibitor of growth 4 induces NFkappaB/p65 ubiquitin-dependent degradation. Oncogene. 2014;33:1997–2003.CrossRefPubMed
51.
Nozell S, Laver T, Moseley D, Nowoslawski L, De Vos M, Atkinson GP, et al. The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol Cell Biol. 2008;28:6632–45.CrossRefPubMedPubMedCentral
52.
Tang Y, Cheng Y, Martinka M, Ong CJ, Li G. Prognostic significance of KAI1/CD82 in human melanoma and its role in cell migration and invasion through the regulation of ING4. Carcinogenesis. 2014;35:86–95.CrossRefPubMed
53.
Coles AH, Gannon H, Cerny A, Kurt-Jones E, Jones SN. Inhibitor of growth-4 promotes IkappaB promoter activation to suppress NF-kappaB signaling and innate immunity. Proc Natl Acad Sci U S A. 2010;107:11423–8.CrossRefPubMedPubMedCentral
54.
Li S, Fan T, Liu H, Chen J, Qin C, Ren X. Tumor suppressor ING4 overexpression contributes to proliferation and invasion inhibition in gastric carcinoma by suppressing the NF-kappaB signaling pathway. Mol Biol Rep. 2013;40:5723–32.CrossRefPubMed
55.
Raho G, Miranda C, Tamborini E, Pierotti MA, Greco A. Detection of novel mRNA splice variants of human ING4 tumor suppressor gene. Oncogene. 2007;26:5247–57.CrossRefPubMed
56.
Loginov VI, Maliukova AV, Seregin Iu A, Khodyrev DS, Kazubskaia TP, Ermilova VD, et al. Methylation of the promoter region of the RASSF1A gene, a candidate tumor suppressor, in primary epithelial tumors. Mol Biol. 2004;38:654–67.CrossRef
57.
Iizuka M, Stillman B. Histone acetyltransferase HBO1 interacts with the ORC1 subunit of the human initiator protein. J Biol Chem. 1999;274:23027–34.CrossRefPubMed
58.
59.
Avvakumov N, Cote J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene. 2007;26:5395–407.CrossRefPubMed
60.
Saksouk N, Avvakumov N, Champagne KS, Hung T, Doyon Y, Cayrou C, et al. HBO1 HAT complexes target chromatin throughout gene coding regions via multiple PHD finger interactions with histone H3 tail. Mol Cell. 2009;33:257–65.CrossRefPubMedPubMedCentral
61.
Palacios A, Munoz IG, Pantoja-Uceda D, Marcaida MJ, Torres D, Martin-Garcia JM, et al. Molecular basis of histone H3K4me3 recognition by ING4. J Biol Chem. 2008;283:15956–64.CrossRefPubMedPubMedCentral
62.
Shi X, Hong T, Walter KL, Ewalt M, Michishita E, Hung T, et al. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature. 2006;442:96–9.CrossRefPubMedPubMedCentral
63.
Hung T, Binda O, Champagne KS, Kuo AJ, Johnson K, Chang HY, et al. ING4 mediates crosstalk between histone H3 K4 trimethylation and H3 acetylation to attenuate cellular transformation. Mol Cell. 2009;33:248–56.CrossRefPubMedPubMedCentral
64.
Foy RL, Song IY, Chitalia VC, Cohen HT, Saksouk N, Cayrou C, et al. Role of Jade-1 in the histone acetyltransferase (HAT) HBO1 complex. J Biol Chem. 2008;283:28817–26.CrossRefPubMedPubMedCentral
65.
Zhang X, Wang KS, Wang ZQ, Xu LS, Wang QW, Chen F, et al. Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem Biophys Res Commun. 2005;331:1032–8.CrossRefPubMed
66.
Guo Y, Meng X, Wang Q, Wang Y, Shang H. The ING4 binding with p53 and induced p53 acetylation were attenuated by human papillomavirus 16 E6. PLoS One. 2013;8, e71453.CrossRefPubMedPubMedCentral
67.
Guo Q, Fast W. Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53. J Biol Chem. 2011;286:17069–78.CrossRefPubMedPubMedCentral
68.
Liao B, Hu Y, Brewer G. Competitive binding of AUF1 and TIAR to MYC mRNA controls its translation. Nat Struct Mol Biol. 2007;14:511–8.CrossRefPubMed
69.
Lu M, Pan C, Zhang L, Ding C, Chen F, Wang Q, et al. ING4 inhibits the translation of proto-oncogene MYC by interacting with AUF1. FEBS Lett. 2013;587:1597–604.CrossRefPubMed
70.
Ozer A, Bruick RK. Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumor suppressor protein ING4. Cell Cycle. 2005;4:1153–6.CrossRefPubMed
71.
Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood. 2007;110:4464–75.CrossRefPubMed
72.
Lu J, Tang Y, Cheng Y, Zhang G, Yip A, Martinka M, et al. ING4 regulates JWA in angiogenesis and their prognostic value in melanoma patients. Br J Cancer. 2013;109:2842–52.CrossRefPubMedPubMedCentral
73.
74.
75.
Zhang X, Zhu W, Zhang J, Huo S, Zhou L, Gu Z, et al. MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res Commun. 2010;395:275–80.CrossRefPubMed
76.
Huang JY, Cui SY, Chen YT, Song HZ, Huang GC, Feng B, et al. MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One. 2013;8, e72615.CrossRefPubMedPubMedCentral
77.
Mraz M, Dolezalova D, Plevova K, Stano Kozubik K, Mayerova V, Cerna K, et al. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood. 2012;119:2110–3.CrossRefPubMed
78.
Loesch K, Galaviz S, Hamoui Z, Clanton R, Akabani G, Deveau M, et al. Functional genomics screening utilizing mutant mouse embryonic stem cells identifies novel radiation-response genes. PLoS One. 2015;10, e0120534.CrossRefPubMedPubMedCentral
79.
Zhao Y, Su C, Zhai H, Tian Y, Sheng W, Miao J, et al. Synergistic antitumor effect of adenovirus-mediated hING4 gene therapy and (125)I radiation therapy on pancreatic cancer. Cancer Lett. 2012;316:211–8.CrossRefPubMed
80.
Huang JH, Ling CH, Yang JC, Zhao DG, Xie YF, Sheng WH. The in vitro and in vivo effects of adenovirus-mediated inhibitor of growth 4 and interleukin-24 co-expression on the radiosensitivity of human lung adenocarcinoma. Zhonghua Jie He He Hu Xi Za Zhi. 2011;34:413–8.PubMed
81.
Wang R, Huang J, Feng B, De W, Chen L. Identification of ING4 (inhibitor of growth 4) as a modulator of docetaxel sensitivity in human lung adenocarcinoma. Mol Med. 2012;18:874–86.PubMedPubMedCentral
Metadata
Title
Inhibitor of growth-4 is a potential target for cancer therapy
Authors
Shuping Yuan
Jianhua Jin
Juanjuan Shi
Yongzhong Hou
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4842-3

Other articles of this Issue 4/2016

Tumor Biology 4/2016 Go to the issue

Original Article

Down-regulation of succinate dehydrogenase subunit B and up-regulation of pyruvate dehydrogenase kinase 1 predicts poor prognosis in recurrent nasopharyngeal carcinoma

Original Article

The dual induction of apoptosis and autophagy by SZC014, a synthetic oleanolic acid derivative, in gastric cancer cells via NF-κB pathway

Original Article

Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers

Original Article

Prognostic value of preoperative lymphocyte to monocyte ratio in patients with nonmetastatic clear cell renal cell carcinoma

Original Article

Identification of CTNNB1 mutations, CTNNB1 amplifications, and an Axin2 splice variant in juvenile angiofibromas

Original Article

Association of promoter polymorphisms of Fas –FasL genes with development of Chronic Myeloid Leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits